Similar articles for PMID: 25143023

Year	Number of Results
1998	2
1999	1
2002	1
2003	2
2004	3
2005	1
2006	4
2007	11
2008	23
2009	17
2010	39
2011	22
2012	28
2013	27
2014	33
2015	31
2016	31
2017	29
2018	23
2019	24
2020	18
2021	12
2022	11
2023	4
2024	0

1

Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.

Gazzola L, Cicconi P, Ripamonti D, Di Filippo E, Gustinetti G, Di Biagio A, Marchetti G, Bini T, d'Arminio Monforte A. Gazzola L, et al. HIV Clin Trials. 2014 Jul-Aug;15(4):140-50. doi: 10.1310/hct1504-140. HIV Clin Trials. 2014. PMID: 25143023

2

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.

Ruane PJ, Brinson C, Ramgopal M, Ryan R, Coate B, Cho M, Kakuda TN, Anderson D; INROADS study investigators. Ruane PJ, et al. HIV Med. 2015 May;16(5):288-96. doi: 10.1111/hiv.12211. Epub 2015 Jan 14. HIV Med. 2015. PMID: 25585528 Free article. Clinical Trial.

3

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B. Boffito M, et al. AIDS. 2007 Jul 11;21(11):1449-55. doi: 10.1097/QAD.0b013e3282170ab1. AIDS. 2007. PMID: 17589191

4

A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).

Ruane P, Alas B, Ryan R, Perniciaro A, Witek J. Ruane P, et al. AIDS Res Hum Retroviruses. 2010 Nov;26(11):1215-9. doi: 10.1089/aid.2009.0285. AIDS Res Hum Retroviruses. 2010. PMID: 21083412 Clinical Trial.

5

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Yazdanpanah Y, et al. Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210. Clin Infect Dis. 2009. PMID: 19814627 Clinical Trial.

6

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group. Madeddu G, et al. Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5. Infection. 2017. PMID: 28477212

7

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group. Vingerhoets J, et al. HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14. HIV Med. 2015. PMID: 25585664 Free article. Clinical Trial.

8

Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.

Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, Re MC, Conti M, Viale P. Calza L, et al. HIV Clin Trials. 2016 Feb;17(1):38-47. doi: 10.1080/15284336.2015.1122874. Epub 2016 Jan 5. HIV Clin Trials. 2016. PMID: 26728706

9

Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.

Hull MW, Montaner JS. Hull MW, et al. Expert Opin Pharmacother. 2010 Jun;11(8):1433-7. doi: 10.1517/14656561003724754. Expert Opin Pharmacother. 2010. PMID: 20367279

10

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F. Sension M, et al. HIV Med. 2013 Aug;14(7):437-44. doi: 10.1111/hiv.12024. Epub 2013 Mar 10. HIV Med. 2013. PMID: 23480640 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

356 results

Results by year